ZYXI - Zynex, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
3.07
-0.03 (-0.97%)
As of 1:58PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close3.10
Open3.10
Bid0.00 x 0
Ask0.00 x 0
Day's Range3.00 - 3.10
52 Week Range0.33 - 5.50
Volume39,522
Avg. Volume26,080
Market Cap100.147M
Beta1.05
PE Ratio (TTM)13.95
EPS (TTM)0.22
Earnings DateMay 14, 2018 - May 18, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2014-06-17
1y Target Est6.35
Trade prices are not sourced from all markets
  • Zynex Recognized in Top 100 Public Companies by ColoradoBiz
    PR Newswire2 days ago

    Zynex Recognized in Top 100 Public Companies by ColoradoBiz

    ENGLEWOOD, Colo., May 23, 2018 /PRNewswire/ -- Zynex (ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurodiagnostic equipment, today announced that ColoradoBiz Magazine has recognized Zynex as a Top100 Public Company in its May/June 2018 issue. Zynex was ranked 83rd on 2017 revenue of $23.4 million up from 90th in 2016 on $13.3 million in revenue. For over 45 years, state officials, company executives and business professionals have looked to ColoradoBiz as the statewide voice of our business community.

  • ACCESSWIRE7 days ago

    Consilium Global Research Issues Quarterly Update on Zynex, Inc (OTCQB: ZYXI)

    ST. PETERSBURG, FL / ACCESSWIRE / May 18, 2018 / Consilium Global Research (CGR) an Investor Recognition Company that connects Companies with Investors, today announced that it has issued an Update Report ...

  • ACCESSWIRE10 days ago

    SeeThruEquity Issues Update on Zynex, Inc.

    NEW YORK, NY / ACCESSWIRE / May 15, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update on Zynex, Inc. (ZYXI). Based in Lone Tree, CO, Zynex, Inc. (ZYXI), "Zynex" produces medical devices that utilize electrotherapy to treat pain and rehabilitation. The company's flagship product, NexWave™, is an FDA-cleared electrotherapy medical device that offers non-invasive, non-addictive treatment of chronic and acute pain.

  • Zynex Announces Share Buyback Program
    PR Newswire11 days ago

    Zynex Announces Share Buyback Program

    ENGLEWOOD, Colo., May 14, 2018 /PRNewswire/ -- Zynex, Inc. (ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced that its board of directors approved a program to buy back an additional $2 million of the Company's common stock.  The new program will commence on May 14, 2018 and is scheduled to terminate on May 13, 2019 or when the $2 million buyback limit is reached. The Company previously re-purchased 495,091 shares of its common stock under a prior buyback program from December 6, 2017 through March 6, 2018. In making the announcement, Zynex President and CEO Thomas Sandgaard stated, "We are committed to delivering shareholder value, and this buyback program authorization reflects the board's confidence in both our short-term prospects and our long term growth strategy.

  • Zynex Announces 2018 First Quarter Earnings
    PR Newswire17 days ago

    Zynex Announces 2018 First Quarter Earnings

    - Revenue grew 100% year over year to $6.9 million - Net income of $1.9 million increased 444% year over year; Diluted EPS $0.06 - Adjusted EBITDA of $2.0 million increased 257% year over year - Seventh ...

  • Zynex Schedules 2018 First Quarter Earnings Release and Webcast
    PR Newswire24 days ago

    Zynex Schedules 2018 First Quarter Earnings Release and Webcast

    LONE TREE, Colo. , May 1, 2018 /PRNewswire/ -- Zynex (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, ...

  • OTCQX And OTCQB Companies to Present At 2018 ROTH Conference
    PR Newswire3 months ago

    OTCQX And OTCQB Companies to Present At 2018 ROTH Conference

    OTC Markets Group EVP Jason Paltrowitz to Speak on Panel on "Reg A+ Offerings" NEW YORK , March 8, 2018 /PRNewswire/ -- OTC Markets Group Inc.  (OTCQX: OTCM), operator of financial markets for ...

  • ACCESSWIRE3 months ago

    Consilium Global Research Issues Quarterly Update on Zynex, Inc (OTCQB: ZYXI)

    ST. PETERSBURG, FL / ACCESSWIRE / March 8, 2018 / Consilium Global Research (CGR) an Investor Recognition Company that connects Companies with Investors, today announced that it has issued an Update Report ...

  • ACCESSWIRE3 months ago

    SeeThruEquity Issues Update on Zynex, Inc.

    NEW YORK, NY / ACCESSWIRE / March 7, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued ...

  • Zynex Appoints New Independent Board Member
    PR Newswire3 months ago

    Zynex Appoints New Independent Board Member

    ENGLEWOOD, Colo., March 6, 2018 /PRNewswire/ -- Zynex, Inc. (ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced the appointment of Joshua R. Disbrow to its Board of Directors and Audit Committee. Mr. Disbrow has been in the life sciences industry for over twenty years across pharmaceuticals, diagnostics, and medical devices. Currently, Mr. Disbrow serves as the Chairman and Chief Executive Officer of Aytu BioScience, Inc. ("Aytu" NASDAQ: AYTU), a commercial-stage specialty life sciences company focused on global commercialization of novel products in the field of urology.  Prior to forming Aytu, Mr. Disbrow was the Chief Operating Officer of Ampio Pharmaceuticals ("Ampio", a NASDAQ traded company) and led the Luoxis Diagnostics subsidiary "Luoxis").

  • ACCESSWIRE3 months ago

    Emerging Developments: New Research on OptimizeRx and Zynex - A Look Ahead into 2018

    NEW YORK, NY / ACCESSWIRE / March 5 , 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of OptimizeRx Corp. (OTCQB: OPRX) and Zynex Inc. (OTCQB: ZYXI), including ...

  • Zynex Announces 2017 Fourth Quarter Earnings
    PR Newswire3 months ago

    Zynex Announces 2017 Fourth Quarter Earnings

    - Revenue grew 178% year over year to $8.1 million - Net income of $3.3 million increased 1,482% year over year; EPS $0.10 - Adjusted EBITDA of $3.9 million increased 481% year over year - Sixth consecutive ...

  • Zynex Schedules 2017 Fourth Quarter and Full Year Earnings Release and Webcast
    PR Newswire3 months ago

    Zynex Schedules 2017 Fourth Quarter and Full Year Earnings Release and Webcast

    LONE TREE, Colo. , Feb. 22, 2018 /PRNewswire/ -- Zynex (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, ...

  • Zynex introduces the NeuroMove™ Device to its expanding sales force
    PR Newswire4 months ago

    Zynex introduces the NeuroMove™ Device to its expanding sales force

    LONE TREE, Colo., Feb. 1, 2018 /PRNewswire/ -- Zynex, Inc. (ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced the introduction of the NeuroMove device into its expanding direct sales force in the US market. The NeuroMove™ is a device designed to aid stroke survivors regain movement using the brain's ability to rewire itself, also known as "neuro-plasticity". Thomas Sandgaard, Founder and CEO, explains: "I am excited to announce that we are re-launching the NeuroMove 900 stroke and traumatic brain injury rehabilitation product to our sales force over the next couple of months.  We have for many years sold the NeuroMove device primarily to rehabilitation clinics in the US as well as internationally and while the device is designed with home use in mind we have not previously promoted it through our direct sales force.

  • ACCESSWIRE4 months ago

    SeeThruEquity Issues Update on Zynex, Inc.

    NEW YORK, NY / ACCESSWIRE / January 16, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has ...

  • Zynex Appoints Two New Independent Board of Directors
    PR Newswire4 months ago

    Zynex Appoints Two New Independent Board of Directors

    LONE TREE, Colo., Jan. 12, 2018 /PRNewswire/ -- Zynex, Inc. (ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced the appointment of Michael Cress, and Barry Michaels to its Board of Directors and Audit Committee. Barry Michaels will also serve as Audit Committee Chair.

  • Zynex Announces 4th Quarter and Year-End Revenue Guidance Update
    PR Newswire5 months ago

    Zynex Announces 4th Quarter and Year-End Revenue Guidance Update

    LONE TREE, Colo., Jan. 8, 2018 /PRNewswire/ -- Zynex, Inc. (ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced an update to its previously announced revenue estimate for the fourth quarter. Zynex updates its Fourth Quarter Revenue Estimate to between $7.5 and $8.0 million. The revenue in the fourth quarter of 2016 was $2.9 million and the most recent third quarter of 2017 was $6.8 million.

  • Zynex, Inc. :ZYXI-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018
    Capital Cube5 months ago

    Zynex, Inc. :ZYXI-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018

    Categories: Yahoo FinanceGet free summary analysis Zynex, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Zynex, Inc. – Medtronic plc (MDT-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 6.82 million, Net Earnings of USD 2.20 million. Gross margins ... Read more (Read more...)

  • A Growing Medical Device Player Aiming to Rule the $6.3 Billion Pain Market; An Exclusive Interview with Zynex CEO Thomas Sandgaard
    SmarterAnalyst5 months ago

    A Growing Medical Device Player Aiming to Rule the $6.3 Billion Pain Market; An Exclusive Interview with Zynex CEO Thomas Sandgaard

    Before founding Zynex, Inc. (OTCMKTS:ZYXI) over two decades ago, Thomas Sandgaard was a man who had just moved to the U.S. from Denmark, starting in a one-bedroom apartment, only a humble few thousand dollars to his name. On back of an MBA from Copenhagen Business school and an electrical engineering degree from the University of Southern Denmark, Sandgaard "bootstrapped" his Lone Tree-based medical device maker to become a leading medical device company in the healthcare industry. Present-day, Zynex continues to grow, with Sandgaard suddenly finding a new need to lease a bigger office and manufacturing space, his eyes on even more gains down the line.

  • ACCESSWIRE5 months ago

    Consilium Global Research Initiates Coverage of Zynex, Inc (OTCQB: ZYXI)

    ST. PETERSBURG, FL / ACCESSWIRE / December 13, 2017 / Consilium Global Research (CGR) an Investor Recognition Company that connects Companies with Investors, today announced that it has issued an Initiation ...

  • Zynex Announces Share Buyback Program
    PR Newswire6 months ago

    Zynex Announces Share Buyback Program

    LONE TREE, Colo., Dec. 6, 2017 /PRNewswire/ -- Zynex, Inc. (ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced that its board of directors approved a program to buy back up to $2 million of the Company's common stock. In making the announcement, Zynex President and CEO Thomas Sandgaard stated, "We are committed to delivering shareholder value, and this buyback program authorization reflects the board's confidence in both our short-term prospects and our long term growth strategy.

  • ACCESSWIRE6 months ago

    Zynex to Present at the 10th Annual LD Micro Main Event

    LOS ANGELES, CA / ACCESSWIRE / November 29, 2017 / Zynex (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, ...

  • ACCESSWIRE6 months ago

    SeeThruEquity Issues Update on Zynex, Inc., Raising Price Target to $5.00

    NEW YORK, NY / ACCESSWIRE / November 28, 2017 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has ...

  • Zynex Announces Webinar to Address the US Opioid Epidemic
    PR Newswire6 months ago

    Zynex Announces Webinar to Address the US Opioid Epidemic

    LONE TREE, Colo., Nov 28, 2017 /PRNewswire/ -- Zynex (ZYXI) is an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics. The company continues to introduce several new products to its product portfolio in its efforts to address the pain and rehabilitation markets and the current opioid epidemic. The current Opioid Epidemic has been declared a health emergency and Zynex is uniquely positioned to help reduce the amount of opioids prescribed for treatment of chronic and acute pain symptoms.  We are hosting a national webinar to reach more healthcare practitioners who are prescribing opioids and give them a true alternative pain relief choice over opioids.  The Zynex product line, offers relief for chronic and acute pain without side-effects, the risk of addiction or death.  The webinar will not only inform practitioners about the benefits our products, but will introduce them to our EZ-Prescribe program which makes prescribing our products faster and easier for practitioners and patients.

  • Zynex Announces 2017 Third Quarter Earnings
    PR Newswire6 months ago

    Zynex Announces 2017 Third Quarter Earnings

    * Revenue grew 88% year over year to $6.8 million * Net income of $2.2 million increased 314% year over year; EPS $0.07 * Adjusted EBITDA of $3.1 million increased 319% year over year * Fifth consecutive ...